Mariner
BLUE

Mariner’s bluebird bio BLUE Stock Holding History

Mariner’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,772
Closed -$28.8K – 3399
2024
Q3 		$28.8K Hold
2,772
– – ﹤0.01% 3228
2024
Q2 		$54.6K Sell
2,772
-90
-3% -$1.8K ﹤0.01% 3041
2024
Q1 		$73.3K Sell
2,862
-26
-0.9% -$666 ﹤0.01% 2981
2023
Q4 		$79.7K Buy
2,888
+102
+4% +$6.22K ﹤0.01% 2888
2023
Q3 		$169K Buy
2,786
+1,003
+56% +$70.5K ﹤0.01% 2569
2023
Q2 		$117K Sell
1,783
-192
-10% -$14K ﹤0.01% 2602
2023
Q1 		$126K Buy
1,975
+1,076
+120% +$123K ﹤0.01% 2528
2022
Q4 		$124K Buy
899
+103
+13% +$14.5K ﹤0.01% 2469
2022
Q3 		$101K Buy
+796
New +$90.1K ﹤0.01% 2200
2019
Q3 		– Sell
-181
Closed -$298K – 727
2019
Q2 		$298K Sell
181
-4
-2% -$6.92K ﹤0.01% 887
2019
Q1 		$378K Buy
+185
New +$326K 0.01% 739

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Mariner's BLUE Position: Q4 2024 in Review

Mariner sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 2,772 shares — an estimated $28.8K sold.

Mariner first reported a position in BLUE in Q1 2019 and held it in 11 quarters. The position peaked at $378K in Q1 2019. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • Mariner reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • Mariner sold 2,772 bluebird bio shares in Q4 2024, an estimated $28.8K.
  • Mariner first reported a position in bluebird bio in Q1 2019 and held it in 11 quarters.
  • Mariner's bluebird bio position peaked at $378K in Q1 2019.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on Mariner's 13F filing for Q4 2024, filed 13 Feb 2025.